Menu
Recruiting NCT01898039

Modified Vaccine for High Risk or Low Residual Melanoma Patients

Phase I / Phase II Interventional Malignant Melanoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: A2/4-1BBL melanoma vaccine, DNP sensititzation, Cyclophosphamide.
Who it may be relevant to
Registry conditions: Malignant Melanoma. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Israel
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients - Phase I/II Study.

Overview

This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence. These patients will be treated with the A2/4-1BBL melanoma vaccine, a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation. The hypothesis that drives the study states that the immune response against the cell line will also be effective against the residual tumor that may still be present in the body.

Interventions

  • Biological A2/4-1BBL melanoma vaccine
    On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
  • Procedure DNP sensititzation
    Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site. On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.
  • Drug Cyclophosphamide
    On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.

Primary outcome measures

  • grade 2-4 adverse events according to CTCEA criteria [Time frame: Day 1]
  • monitoring anti-tumor immune response [Time frame: Day 0]
  • grade 2-4 adverse events according to CTCEA criteria [Time frame: Day 28]
  • grade 2-4 adverse events according to CTCEA criteria [Time frame: Day 56]
  • grade 2-4 adverse events according to CTCEA criteria [Time frame: month 3]
  • grade 2-4 adverse events according to CTCEA criteria [Time frame: month 4]
  • grade 2-4 adverse events according to CTCEA criteria [Time frame: month 5]
  • grade 2-4 adverse events according to CTCEA criteria [Time frame: month 6]
  • monitoring anti-tumor immune response [Time frame: Day 28]
  • monitoring anti-tumor immune response [Time frame: Day 56]
Secondary outcome measures (1)
  • overall survival and disease free survival [Time frame: D1, Mo6, Mo10, Mo14, Mo18, Mo20, Mo24 and every 4 months till year 5]

Eligibility criteria

Inclusion criteria

  • Patients included in this protocol must carry one or more of the following tissue typing alleles: HLA-A2, -A24, -A33, -B35, -B49, -CW04/12(04/08). We estimate that 50% of melanoma patients will be eligible.
  • Cutaneous malignant melanoma AJCC stage IIb (>4 mm) or IIc (ulcerated melanoma >4mm).
  • Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post-surgical removal of lymph nodes.
  • Metastatic melanoma AJCC stage IV, completely resected.
  • Non-resectable metastatic melanoma of low burden disease and normal LDH who have undergone at least two treatment lines, including chemotherapy (DTIC, temodal, taxanes, platinum compounds), anti-CTLA-4 (ipilimumab) and B-RAF inhibitor if harboring the V600E BRAF mutation in their tumor.
  • Non cutaneous malignant melanoma of respective stages including uveal and mucosal melanoma.
  • Melanoma can be of either mutant or wild-type B-RAF.
  • Karnofsky performance status > 80 (Normal activity with effort).
  • No active cardio-respiratory disease.
  • Not pregnant or nursing. Women must take contraceptives during the treatment period.Hematocrit >25% and WBC >3000.
  • Informed consent of the patient.

Exclusion criteria

  • Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior to protocol administration.
  • Active brain metastases requiring corticosteroids.
  • Concurrent malignancy (other than skin cancer, carcinoma in situ of cervix and early stage prostate cancer).
  • Active serious infection.
  • Allergy to penicillin.
  • Patient's will to withdraw from the study at any stage.
  • HIV and chronic hepatitis B and C carrier

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Israel · 1 center
  • Sharett Institute of Oncology, Hadassah Medical Organization — Jerusalem

Identifiers

NCT: NCT01898039 · 0419-12-HMO-CTIL

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗